EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Coagulation factor V in breast cancer: a p53-regulated tumor suppressor and predictive marker for treatment response to chemotherapy

Sara Marie Lind, Marit Sletten, Mona Hellenes, Anthony Mathelier, Xavier Tekpli, Mari Tinholt, Nina Iversen

Journal of Thrombosis and Haemostasis · 2024

DOI: 10.1016/j.jtha.2024.02.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Sara Marie Lind und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway. Hauptthemen laut MEDLINE: Breast Neoplasms, Factor V, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with cancer are at an increased risk of developing coagulation complications, and chemotherapy treatment increases the risk. Tumor progression is closely linked to the hemostatic system. Breast cancer tumors express coagulation factor V (FV), an essential factor in blood coagulation. The functional role of FV during treatment with chemotherapy is poorly understood and was explored in this study. OBJECTIVES: We aimed to investigate the role of FV in breast cancer progression by exploring associations with treatment response, gene regulation, and the functional effects of FV. METHODS: The receiver operating characteristic plotter was used to explore the predictive value of FV mRNA (F5) expression for treatment with FEC (5-fluorouracil, anthracycline, and cyclophosphamide). Breast cancer cohorts were analyzed to study treatment response to FEC. The effect of chemotherapy on F5 expression, the regulation of F5, and the functional effects of FV dependent and independent of chemotherapy were studied in breast cancer cell lines. RESULTS: F5 tumor expression was significantly higher in responders to FEC than in nonresponders. In vitro experiments revealed that anthracycline treatment increased the expression of F5. Inhibition and knockdown of p53 reduced the anthracycline-induced F5 expression. Mutation of a p53 half-site (c.158+1541/158+1564) in a luciferase plasmid reduced luciferase activity, suggesting that p53 plays a role in regulating F5. FV overexpression increased apoptosis and reduced proliferation slightly during anthracycline treatment. CONCLUSION: Our study identified F5 as a p53-regulated tumor suppressor candidate and a promising marker for response to chemotherapy. FV may have functional effects that are therapeutically relevant in breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsFactor VGene Expression Regulation, NeoplasticTumor Suppressor Protein p53FemaleHumansAntineoplastic Combined Chemotherapy ProtocolsApoptosisBiomarkers, TumorBlood CoagulationCell Line, TumorCell ProliferationCyclophosphamideEpirubicinFluorouracilMCF-7 CellsMutationRNA, MessengerTreatment Outcome

Stichwörter der Autor:innen

biomarkerbreast cancerfactor Vneoadjuvant chemotherapy treatmentp53 tumor suppressor protein

Substanzen

Biomarkers, TumorCyclophosphamideEpirubicinFactor VFluorouracilRNA, MessengerTP53 protein, humanTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway.
  • Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway; Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo, Oslo, Norway.
  • Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway. Electronic address: uxnaiv@ous-hf.no.

Zitieren

APA

Lind, S. M., Sletten, M., Hellenes, M., Mathelier, A., Tekpli, X., Tinholt, M., & Iversen, N. (2024). Coagulation factor V in breast cancer: a p53-regulated tumor suppressor and predictive marker for treatment response to chemotherapy. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.02.008

Vancouver

Lind SM, Sletten M, Hellenes M, Mathelier A, Tekpli X, Tinholt M, et al. Coagulation factor V in breast cancer: a p53-regulated tumor suppressor and predictive marker for treatment response to chemotherapy. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.02.008

BibTeX
@article{Lind2024,
  author = {Lind, Sara Marie and Sletten, Marit and Hellenes, Mona and Mathelier, Anthony and Tekpli, Xavier and Tinholt, Mari and Iversen, Nina},
  title = {Coagulation factor V in breast cancer: a p53-regulated tumor suppressor and predictive marker for treatment response to chemotherapy},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  doi = {10.1016/j.jtha.2024.02.008}
}
Kostenlos starten →